ANKRD44

ANKRD44 is an ankyrin-repeat scaffold subunit of the protein phosphatase 6 (PP6) holoenzyme, one of three interchangeable ankyrin subunits (with ANKRD28 and ANKRD52) that assemble with the PP6 catalytic subunit and a SAPS-domain regulatory subunit (PP6R1–R3) into a >440 kDa heterotrimer specific to PP6 rather than PP2A or PP4 (PMID:18186651, PMID:39014521). Within this complex, PP6R1 serves as the bridging scaffold, using a C-terminal region to recruit the ankyrin subunit through a site distinct from its PP6 catalytic-binding region (PMID:18186651). Functionally, the PP6–PP6R1–ankyrin complex restrains TNFα-induced degradation of IκBε, positioning ANKRD44 as a negative regulator of NF-κB signaling (PMID:18186651). Consistent with this role, ANKRD44 loss in HER2+ breast cancer cells drives constitutive NF-κB activation through the TAK1/AKT axis, increased glycolysis, and partial trastuzumab resistance (PMID:31297336). ANKRD44 is itself a direct target of miR-133a-3p, and its expression promotes osteogenic differentiation of bone marrow mesenchymal stem cells (PMID:34350837).

1. 2008 High

   Establishing how the PP6 phosphatase is built, this work defined ANKRD44 as one of a family of ankyrin-repeat subunits that assemble with PP6 catalytic and SAPS-domain regulatory subunits into a specific heterotrimer.

   Evidence FLAG co-immunoprecipitation with mass spectrometry, size-exclusion chromatography, and domain-mapping pulldowns using a C-terminal PP6R1 fragment

   PMID:18186651

   Open questions at the time

   • Most assembly data used ANKRD28 as proxy rather than ANKRD44 directly
   • No structural model of the heterotrimer or the ankyrin–PP6R1 interface
   • Functional distinction between the three interchangeable ankyrin subunits not resolved
2. 2008 Medium

   Linking the complex to a signaling output, knockdown placed the PP6–PP6R1–ankyrin assembly upstream of IκBε stability, implicating it as a brake on NF-κB activation.

   Evidence siRNA knockdown of individual PP6 subunits followed by TNFα stimulation and IκBε degradation assay

   PMID:18186651

   Open questions at the time

   • Direct substrate of the phosphatase in this pathway not identified
   • Effect attributed to ANKRD28; ANKRD44-specific contribution not isolated
   • Single lab
3. 2019 Medium

   Extending the NF-κB link to cancer, ANKRD44 loss was shown to drive trastuzumab resistance via constitutive NF-κB activation and metabolic reprogramming in HER2+ breast cancer cells.

   Evidence ANKRD44 siRNA silencing in BT474 cells with trastuzumab resistance, NF-κB, glycolysis, LDHB and TROP2 readouts

   PMID:31297336

   Open questions at the time

   • No rescue experiment to confirm specificity
   • Connection to PP6 phosphatase activity not mechanistically reconstructed
   • TAK1/AKT-to-NF-κB causal chain inferred from correlative readouts
4. 2021 Medium

   Identifying an upstream regulator, ANKRD44 was validated as a direct miR-133a-3p target whose expression promotes osteogenic differentiation.

   Evidence Dual luciferase reporter assay, miR mimic/inhibitor transfection, and ANKRD44 overexpression rescue with ALP and alizarin red staining in BMSCs

   PMID:34350837

   Open questions at the time

   • Downstream effector mechanism in osteogenesis not defined
   • Whether PP6 complex assembly mediates the osteogenic effect untested
   • Single lab
5. 2024 Medium

   Reaffirming complex architecture in a new context, the three-subunit PP6 composition was restated while CSC-regulatory function was attributed to the PP6c–PP6R3 pairing.

   Evidence PP6c siRNA knockdown, transcriptome analysis, sphere-formation and in vivo proliferation assays in colorectal cancer cells

   PMID:39014521

   Open questions at the time

   • Functional experiments centered on PP6c/PP6R3, not ANKRD44 specifically
   • Whether ANKRD44 is the relevant scaffold in this context untested

• Whether ANKRD44's distinct scaffolding role confers substrate or pathway specificity to PP6 beyond the interchangeable ankyrin family remains unresolved.
• No ANKRD44-specific substrate or unique structural determinant identified
• No structural model of the ANKRD44-containing heterotrimer
• Distinct in vivo functions of ANKRD28 vs ANKRD44 vs ANKRD52 not separated